BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced that Ryan Noyce, Ph.D., and David Evans, Professor, Department of Cell Biology, University of Alberta, together with scientists from Tonix presented data from a research collaboration between Tonix Pharmaceuticals and The University of Alberta in a poster presentation at the 4th Symposium of the Canadian Society for Virology held in Edmonton, Alberta, Canada on June 5, 2022.

The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice.

Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to advance treatments that can provide a bridge to a cure for chronic hepatitis B virus (HBV), today announced the acceptance of oral presentations highlighting ATI-2173, Antios’ lead therapeutic HBV candidate .

Ms. Gambale’s experience in data technology and finance supports Avellino’s bioinformatics precision medicine mission.

Completed Phase I dose escalation; results expected in 3Q22.

Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2022 on Wednesday, July 27, 2022. Company executives will review financial results and address inquiries from investors and analysts during a conference call at 8:00 a.m. ET on the same date.

Wilmington, Delaware, United States: According to the report, the global medical equipment rental market was valued at US$ 51.05 Bn in 2020.

Wilmington, Delaware, United States: The digital version of the patient’s paper chart is known as electronic health record.

Wilmington, Delaware, United States: According to the report, the global population health management market was valued at US$ 25.9 Bn in 2020 and is projected to expand at a CAGR of 15.9% from 2021 to 2028.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced that it will be presenting positive data from two Phase 3 clinical trials: the two-year open-label extension of the OPTIMAL study and the MPOWERED study, at the Endocrine Society’s annual meeting, ENDO 2022.